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Background: In the high-prevalence setting of Pakistan, screening, diagnosis and treatment services for
chronic hepatitis C (CHC) patients are commonly offered in specialized facilities. We aimed to describe the cas-
cade of care in a Médecins Sans Frontières primary health care clinic offering CHC care in an informal settle-
ment in Karachi, Pakistan.
Methods: This was a retrospective cohort analysis using routinely collected data. Three different screening
algorithms were assessed among patients with one or more CHC risk factors.
Results: Among the 87 348 patients attending the outpatient clinic, 5003 (6%) presented with one or more
risk factors. Rapid diagnostic test (RDT) positivity was 38% overall. Approximately 60% of the CHC patients
across all risk categories were in the early stage of the disease, with an aspartate aminotransferase:platelet
ratio index score <1. The sequential delays in the cascade differed between the three groups, with the inter-
val between screening and treatment initiation being the shortest in the cohort tested with GeneXpert
onsite.
Conclusions: Delays between screening and treatment can be reduced by putting in place more patient-
centric testing algorithms. New strategies, to better identify and treat the hidden at-risk populations, should
be developed and implemented.
Keywords: hepatitis C, operational research, risk factors, SORT IT, testing and treatment algorithm, time delays
Introduction
Hepatitis C is a major public health problem worldwide, with a
global seroprevalence of 1.6%.1 According to the 2017 World
Health Organization (WHO) global hepatitis report, an estimated
71 million people are living with hepatitis C virus (HCV) infection,
which corresponds to a global prevalence of 1.0%.2 The WHO
Eastern Mediterranean region has the highest reported preva-
lence of HCV of 2.3%, followed by the European region at 1.5%.2
The burden remains particularly high in low- and middle-income
countries (LMICs).3 Chronic hepatitis C (CHC) patients are at
increased risk of developing hepatic ﬁbrosis, cirrhosis and hepato-
cellular carcinoma, and it has been estimated that approximately
1.4 million untreated people die each year.3,4 While the new era
of direct-acting antivirals has dramatically improved the treat-
ment outcomes of CHC patients, and may in the long term even
contribute to bringing the elimination of hepatitis C within reach,
scaling up and streamlining testing services and linkage to care
remain a major hurdle, mainly in LMICs.5,6 Testing services are
particularly challenged by the asymptomatic or non-speciﬁc clin-
ical presentation during acute and early stages of chronic HCV
infections and by the fact that hepatitis C is typically most preva-
lent in marginalized at-risk populations.4,7
Pakistan is among the countries with the highest HCV sero-
prevalence, with approximately 10 million people carrying the
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a prevalence of 4.8%, with the highest rates reported in Punjab
and Sindh provinces.8,9 A systematic review done in 2010
reported the seroprevalence to be even higher, up to 6.8% in the
general population.10 Unscreened blood transfusions and unsafe
medical and dental procedures have been associated with hepa-
titis C transmission in settings where overuse and inappropriate
use of injections in medical practice is common, as is the case in
Pakistan.11 A plethora of other potential risk factors have been
identiﬁed, such as injectable drug use (needle sharing), tattooing
with reused needles, mother-to-child transmission and unpro-
tected sex, all of which may play an important role in different
strata of the population in Pakistan.11–13
Early diagnosis of CHC infection and providing necessary
treatment are crucial to prevent or delay the onset of liver dis-
ease and prevent transmission.14 However, lack of provider and
patient awareness, unavailability of testing sites, limited tech-
nical human resources, concerns about stigma and discrimin-
ation, and high medicine costs all contribute to poor diagnosis
and linkage to care in Pakistan.4,15 HCV screening and treatment
services are mainly provided at the tertiary care level by both
private and public health care providers, but at high cost, which
makes them inaccessible for the marginalized and at-risk popu-
lations who bear the burden of the disease.15,16 Several studies
and systematic reviews have been conducted to describe the
epidemiology of HCV and its associated risk factors in Pakistan,
but limited evidence is available on screening and linkage to
care in a primary health care setting.9,10,17,18 Additionally, while
the contribution of different risk behaviours to HCV transmission
dynamics in general has been described previously, risk beha-
viours among particular populations remain relatively underdo-
cumented, and interventions towards addressing such risk
behaviours are rarely implemented.17,19
The aim of our study was therefore to assess the perform-
ance of the hepatitis C screening programme in a Médecins Sans
Frontières (MSF) primary health care clinic offering CHC diagnosis
and treatment in an informal settlement in Karachi. The speciﬁc
objectives were to describe the cascade of care from screening
to treatment for the at-risk population, determine sociodemo-
graphic characteristics associated with seropositivity, describe
disease staging per risk category and calculate the time interval
between each step of the screening cascade.
Materials and methods
Study design
This was a retrospective cohort analysis of routinely collected
project data.
General setting
Pakistan is a country with a population of 188.1 million and an
estimated population increase of 41% over the last 25 y.20
Almost 62% of the country’s population lives in rural areas and
the majority of the population belongs to low socio-economic
strata, with low literacy rates.20 Huge health disparities and
gaps exist between the rural and urban populations.15 The bur-
den of communicable and non-communicable diseases is rela-
tively high, at 38.3% and 50.5%, respectively.20 In Pakistan,
health care delivery is implemented by the provincial govern-
ment, with the federal government limited to providing tech-
nical assistance, training and policymaking. The state provides
health care via a three-tiered delivery system: basic health units
and rural health centres forming the core of the primary health
care model; secondary care including ﬁrst- and second-level
referral facilities, such as the tehsil and district headquarters
hospitals; and tertiary care teaching hospitals.15
Speciﬁc setting—Karachi and Machar Colony
Karachi is the capital of the Sindh province and represents a
major ﬁnancial and industrial hub of the country, with an esti-
mated population of 14.9 million.21 As the largest city in
Pakistan, it has a number of informal settlements with popula-
tions who live below the poverty line and have limited access to
health care services.22 MSF started working in collaboration with
the local non-governmental organization (NGO) SINA in the
Machar Colony settlement in 2013, providing primary health
care services to the population. SINA is a local NGO that runs
similar clinics (25 in total) and services in other parts of Karachi.
An assessment done by MSF in 2013 investigating the burden of
hepatitis C in the community identiﬁed a high prevalence of key
risk factors for HCV infection (reuse of needles and reports of
intravenous drug use) in this slum area and recommended
starting an HCV screening and treatment programme. The MSF
hepatitis C clinic was started in February 2015, with the object-
ive to provide free-of-cost access to HCV care for the residents
of Machar Colony through a primary health care clinic using sim-
pliﬁed diagnostic and treatment algorithms. Most of the popula-
tion residing in this slum were reported to be undocumented
migrants with very limited access to health care.
MSF hepatitis C clinic
All patients presenting to the primary health care clinic (6 d/
week, 9 h/d) passed by the triage desk, except for pregnant
patients, who went directly to the maternity unit. At the triage
desk, patients were directed to the proper unit (general out-
patient department [OPD], HCV clinic or the vaccination unit).
Box 1. Risk factors for screening
(1) Symptomatic patient
(2) Intravenous drug use
(3) HIV positive
(4) Spouse of HCV-positive patient
(5) Child of HCV-positive mother
(6) Mother of HCV-positive child
(7) History of incarceration
(8) History of jaundice
(9) History of blood transfusion
(10) Major surgeries/dental procedures
(11) Injections/infusions at local clinics
(12) Others (dialysis history, history of minimal invasive
procedures, health care personnel, Men who have sex with
men (MSM))
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All the patients who were sent to the OPD were then rou-
tinely assessed for hepatitis C risk factors by the OPD doctors
(Box 1). Patients who exhibited any signs or symptoms or pre-
sented with a history of any of the risk factors for HCV were fur-
ther referred by the OPD doctor to the lab (situated within the
clinic) for HCV antibody screening using an OraQuick (OraSure
Technologies, Bethlehem, PA, USA) rapid diagnostic test (RDT).
Patients who tested positive on the RDT were then tested by
polymerase chain reaction (PCR) for conﬁrmation of CHC. If the
patient was positive on PCR, she/he was then referred to the
HCV unit (within the same premises) to be assessed or evalu-
ated by the hepatitis C doctor (general practitioner) for treat-
ment initiation based on set eligibility criteria (including
aspartate aminotransferase:platelet ratio index [APRI] score
cut-offs, non-pregnancy, absence of mental health issues). The
APRI score was used as a simple, non-invasive proxy serum
marker to determine the stage of liver ﬁbrosis.13,14 All patients
who qualiﬁed for treatment were subsequently started on
direct-acting antivirals such as sofosbuvir, daclatasvir and riba-
virin according to the MSF clinical protocol based on the WHO
hepatitis C guidelines.7
Patients who were eligible for treatment were also simultan-
eously started on patient support counselling, which included
different sessions (eligibility session, treatment initiation, end of
treatment session, sustained virological response [SVR] session).
In Pakistan during the study period, MSF was the ﬁrst and only
international medical organization to treat patients with the
new direct-acting antivirals (sofosbuvir and daclatasvir), which
are known to have lesser side effects and reduced treatment
duration. Sofosbuvir and daclatasvir were very expensive at that
time, with no generics available in Pakistan. MSF procured this
treatment regimen internationally and provided it for the eligible
patients free of cost with importation approval from the drug
regulatory authority of Pakistan (DRAP); at the time, it was not
even registered in the country.
MSF screening and diagnostic algorithm
The screening and diagnostic algorithm adopted in different
time periods is shown in Figure 1. Before February 2017, all RDT-
positive patients were ﬁrst tested by qualitative PCR at an exter-
nal laboratory (Dow University of Health Sciences): if found to be
positive, the patient underwent APRI scoring and was then
tested for viral load through quantitative PCR, again at the
external laboratory. As a cut-off to establish treatment eligibility,
an APRI >1 was used initially, until October 2016; subsequently
the eligibility threshold was decreased to an APRI >0.5, when it
was observed that an APRI >1 resulted in the exclusion of many
patients from the target population in Machar Colony, as they
tended to have a lower APRI than patients from outside Machar
Colony.
After February 2017, RDT-positive patients were offered HCV
PCR testing internally in the clinic using the GeneXpert HCV Viral
Load assay (GeneXpert 1V system, Cepheid, Sunnyvale, CA, USA)
on the same day as the RDT, followed by APRI staging. Using
the APRI score threshold and the change in testing platform, we
divided the study population into three groups: group 1 (RDT
date before 1 October 2016; APRI cut-off >1), group 2 (RDT date
between 1 October 2016 and 31 January 2017; APRI cut-off
>0.5) and group 3 (RDT date between 1 February 2017 and 30
September 2017; testing by GeneXpert, APRI cut-off >0.5).
Study population
All patients presenting to the MSF OPD clinic in Machar Colony,
Karachi between March 2016 and September 2017 having one
or more risk factors for HCV were included. Patients who came
with an externally provided hepatitis C diagnosis were excluded
from the study. The study population was categorized as RDT
APRI >1, RDT APRI >0.5 and GeneXpert cohorts, respectively,
based on which diagnostic algorithm they underwent.
Data sources and variables
All screening data were extracted from the screening database,
which was routinely entered by data staff in the project. The
Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF
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data for all CHC-positive patients were extracted from the Hepa-
MUD electronic database, which is used as a routine monitoring
and evaluation tool for hepatitis C patients in the project.
Statistical analysis
The clinic identiﬁcation (ID) was used as a unique identiﬁer to
cross-link data from the screening database and Hepa-MUD in
Excel (Microsoft, Redmond, WA, USA); the combined dataset
was then imported into STATA version 14.2 (StataCorp, College
Station, TX, USA) for analysis. Consistency checks were per-
formed for each duplicate ID encountered; if any variable dif-
fered between duplicate IDs, they were coded as separate
patients.
Positivity rates were calculated per risk group category and
were expressed as proportions. For the two RDT cohorts, the
median time intervals were calculated between the RDT date
and qualitative PCR date, between the qualitative PCR date and
quantitative PCR date and between the quantitative PCR date
and treatment initiation date. For the GeneXpert group, we cal-
culated the time interval between the RDT date and quantitative
PCR/GeneXpert dates and between the quantitative PCR/
GeneXpert dates and treatment initiation dates.
If there were missing dates for quantitative PCR/GeneXpert,
we used the APRI score date instead, as quantitative PCR/
GeneXpert testing and blood investigation for APRI scoring were
conducted at the same time. The treatment initiation status
was censored by 28 November 2017.
Associations between seropositivity and patient characteris-
tics (age and sex) were assessed, using logistic regression and
expressed as odds ratios (ORs) with 95% conﬁdence intervals
(CIs). All the study results were reported according to the




Of a total of 87 348 patients seen in the of the MSF-operated
primary health clinic, 5003 (6%) were identiﬁed as having one
or more HCV risk factors and 1901 (38%) of these had a positive
RDT test for HCV. The diagnostic cascade, with positive, negative
and untested proportions at each step, for each of the cohorts
is shown in Figure 2A–C. The treatment initiation rates by the
censor date of those eligible for treatment in the three cohorts
were 75/75 (100%) for patients diagnosed using RDT APRI >1,
82/92 (96%) for patients diagnosed using RDT APRI >0.5 and
22/100 (22%) for patients diagnosed using GeneXpert. Among
the patients testing positive by qualitative PCR in the RDT
cohorts, the APRI score was not recorded in 33% and 29%,
respectively. Among the 752 patients who were RDT-positive in
the GeneXpert cohort, the quantitative PCR results were not
recorded in the electronic database for 617 (82%) patients.
Risk for HCV positivity and disease staging
The overall number of at-risk individuals and the proportions of
seropositive individuals per risk category are shown in Figure 3.
Positivity rates were highest among human immunodeﬁciency
virus (HIV)-positive patients (100%), intravenous drug users
(45%), patients with a history of blood transfusion (40%) and
patients having injections/infusions at local clinics (40%), while
the lowest positivity rate was found in the risk group of children
of hepatitis C–positive mothers (23%).
Among the at-risk population, only sex and age were avail-
able as possible additional exposure variables. Men were more
likely to be seropositive than women, at an adjusted odds ratio
(aOR) of 1.20 (95% CI 1.14–1.26). The age groups 39–58 y and
≥59 y were at higher risk of seropositivity than the age group of
18–38 y, with an aOR of 1.37 (95% CI 1.27–1.48) and 1.61 (95%
CI 1.44–1.80), respectively. Within this group of patients with a
risk factor, individuals related to someone with conﬁrmed HCV
(parent, child or spouse) and individuals with a history of major
surgeries or dental procedures were least at risk of HCV
(Table 1).
Disease staging according to risk category is shown in
Figure 4: approximately 60% of the patients across all risk cat-
egories were in early-stage disease, with an APRI score <1.
Diagnostic delays
In the RDT cohorts, almost 90% of the patients were tested on
the same day by RDT and qualitative PCR; the median interval
between qualitative PCR/APRI staging and quantitative PCR was
50 d (interquartile range [IQR] 29–113) and 81 d (IQR 53–122),
and between quantitative PCR and treatment initiation it was
92 d (IQR 27–133) and 107 d (IQR 64–139), respectively. In the
GeneXpert cohort, the median interval between RDT and
GeneXpert and between GeneXpert and treatment initiation was
2 d (IQR 0–74) and 68 d (IQR 56–120), respectively (Figure 5).
Discussion
The present study reports the feasibility of a simpliﬁed, primary
health care-level, single entry point diagnostic and screening
testing cascade for hepatitis C. Our study demonstrates how
the cascade resulted in a high proportion of treatment-eligible
patients starting treatment. For the cohort assessed through
GeneXpert, only a quarter of the patients who were treatment
eligible were initiated on treatment at the time of censoring; it
is likely that most patients were still on the waiting list by the
censor date, although some may have been lost. While this
study did not assess the patient outcomes after treatment or
the SVR, previous work at this clinic has shown a high treatment
success rate of 83%.29
RDT positivity rates were high overall, at 38%—considerably
higher than the reported seroprevalence of 6.8% in Pakistan,10
which reﬂects the at-risk proﬁle of the study population.
Positivity rates were higher in certain risk groups, including HIV-
positive patients, intravenous drug users, patients with a history
of blood transfusion and patients having injections/infusions at
local clinics. These ﬁndings are in line with previous studies
where seropositivity rates were found to be high among people
who had a history of previous injections, a history of syringe
reuse and a history of blood transfusion.9,17 Other studies in a
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Figure 2. Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, at the MSF Clinic, Karachi, Pakistan, March
2016–September 2017. (a) Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, for patients diagnosed using
RDT APRI >1. (b) Diagnostic and screening cascade for hepatitis C, with positivity rate at each diagnostic step, for patients diagnosed using RDT APRI
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Figure 3. Number and proportion of patients testing seropositive for hepatitis C, by risk group category, at the MSF clinic, Karachi, Pakistan, March
2016–September 2017.
Table 1. Factors associated with hepatitis C seropositivity among all patients with an identiﬁed risk factor of hepatitis C at the MSF clinic,
Karachi, Pakistan, March 2016–September 2017
Characteristics Total, N Seropositive, n (%) aOR (95% CI) p-Value
Sex
Female 3464 1248 (36) 1 –
Male 1528 599 (39) 1.2 (1.1–1.3) <0.001
Age (y)
<20 665 64 (10) 0.1 (0.1–0.2) <0.001
20–29 1074 398 (37) 0.6 (0.5–0.7) <0.001
30–39 1250 437 (35) 1 –
40–49 1223 462 (38) 1.4 (1.2–1.6) <0.001
50–59 600 231 (39) 1.4 (1.2–1.7) 0.001
≥60 327 121 (37) 2.0 (1.5–2.5) <0.001
Risk group
Symptomatic patient 450 176 (39) 1.0 (0.8–1.2) 0.99
Intravenous drug use 38 17 (45) 1.2 (0.6–2.3) 0.7
HIV positive 10 10 (100) – –
Spouse of HCV-positive patient 639 193 (30) 0.5 (0.4–0.7) <0.001
Child of HCV-positive mother 790 184 (23) 0.8 (0.6–1.0) 0.03
Mother of HCV-positive child 68 21 (31) 0.5 (0.3–0.9) 0.02
History of incarceration 46 17 (37) 1.0 (0.5–1.8) 0.9
History of jaundice 703 255 (36) 0.9 (0.7–1.0) 0.09
History of blood transfusion 508 203 (40) 1.0 (0.8–1.2) 0.99
Major surgeries/dental procedures 741 269 (36) 0.7 (0.6–0.8) <0.001
Injections/infusions at local clinics 2833 1141 (40) 1.1 (0.9–1.2) 0.4
Others 165 86 (52) 2.3 (1.6–3.3) <0.001








niversity of Bristol Library user on 03 January 2019
variety of other settings have also shown high seroprevalence
rates in intravenous drug users.24–28
In this study, men had a higher risk of being seropositive and
this risk increased with age. This ﬁnding is comparable to a sur-
vey conducted in Pakistan in 2010.9 Being related to people with
HCV carried the least risk, as well as having undergone major
surgical or dental procedures, although even for these risk
groups the positivity rates were considerably higher than the
estimated HCV prevalence in Pakistan.
The time interval between point of entry (RDT testing) and
care (treatment initiation) in all three algorithms was different
and was shortest in the GeneXpert cohort, as onsite GeneXpert
was implemented. Removing one step in the algorithm could
reduce the time interval between the RDT test and treatment ini-
tiation from >180 d to 70 d. However, the increase of the delay
in the ﬁrst step of the cascade (from 0 d to 2 d) may reﬂect low
lab capacity to process all samples in a timely manner, and other
sites considering implementation of GeneXpert may need to
consider the anticipated sample load when setting up their
services.
The study did not come without certain limitations. First, cer-
tain exposure variables relevant to the project were not avail-
able, such as patient origin, marital status and employment
status. In many patients, the results were not recorded in an
electronic database and it was not possible to differentiate
between patients who did not come back to the clinic (pretreat-
ment attrition) and patients for whom data were not entered.
Second, the study was undertaken in one MSF-supported site,
where care was offered free of charge, and therefore the data
may not be representative of public clinics in similar settings.
Third, the risk factors recorded in the project were self-reported,
and stigmatizing risk factors (HIV infection, intravenous drug
use, history of incarceration) may thus have remained under-
reported. Fourth, no prevalence study was conducted in the
Figure 4. Disease staging for CHC infection, by risk category, at the MSF clinic, Karachi, Pakistan, March 2016–September 2017.
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overall population attending the MSF-supported clinic, and the
performance of the risk groups as a means of identifying indivi-
duals at exceptional risk for HCV could thus not be evaluated.
Our study ﬁndings suggest that the screening algorithm
recommended by the WHO and implemented by the MSF pro-
ject in a primary health care setting is a robust one and can
work well in most settings.2 Streamlining and simplifying the
diagnostic and testing algorithms can beneﬁt patients and pro-
vide direct and easy access to the point of care. Additionally,
decreasing the delays in the pathway to care will decrease pre-
treatment attrition, which has been shown earlier to be sizeable
in this type of population.29 However, more work is needed to
reduce the diagnostic process further to a single-stop diagnostic
step, thus reducing the possibility of patient losses during the
waiting periods between steps. Collaboration with programmes
such as HIV/acquired immune deﬁciency syndrome (AIDS) and
tuberculosis (TB) control programmes can signiﬁcantly reduce
the burden of buying and maintaining the GeneXpert machines.
Additionally, such collaborations could lead to many patients
within the HIV/AIDS and TB programmes being tested for HCV
under one roof.
Several additional recommendations can be drawn from our
study. Internally, from the programme perspective, the data
recording system needs to be strengthened and routine data
quality should be assured to minimize missing data.
Additionally, speciﬁc issues on the risk criteria for hepatitis C
were identiﬁed. Some of the groups with the highest positivity
rates are also the least likely to self-declare their risk proﬁle,
such as individuals with a history of incarceration or people who
inject drugs, and the overall numbers identiﬁed by applying
these risk categories remain low. Other risk groups have a higher
‘yield’ of total positive cases but lower positivity rates. As the
positivity rates per risk group stay well above the estimated
prevalence of hepatitis C in Pakistan, they can be considered a
tool of some worth in screening for CHC, but they remain too
non-speciﬁc to contribute sizably to reducing the burden in a
setting such as the informal settlements in Karachi. The high
positivity rate in the ‘other’ risk group category suggests that
this group merits further exploration. More speciﬁc deﬁnitions of
populations at risk are urgently needed, as well as strategies to
actively reach high-risk populations such as people who inject
drugs and people living with HIV, but also the older age groups.
Improvement strategies could include integrating hepatitis C
screening and testing services in risk group–targeted activities,
such as needle and syringe exchange programmes for intraven-
ous drug users, and HIV care and treatment centres. To be able
to provide strong evidence on the effectiveness of the testing
algorithms used, cost-effectiveness studies comparing the dif-
ferent screening strategies should also be considered.
Conclusions
This study documents for the ﬁrst time the screening and diag-
nostic cascade of care for CHC integrated in a primary health
clinic. It illustrates the time gains that can be achieved by bring-
ing molecular diagnosis to the point of testing and the success
of this strategy in linking patients to care. The use of risk cat-
egories to identify individuals who may beneﬁt from screening is
a key component in this process, and new strategies to better
access existing but hidden at-risk populations are urgently
needed. Further efforts are needed to reduce the delay between
CHC conﬁrmation and HCV treatment initiation, which was still
long even when the delay between screening and linkage to
care was dramatically reduced. This may be ensured by a great-
er availability of affordable new pan-genotypic direct-acting
antiviral combinations and further simpliﬁcation of treatment
follow-up.
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